Business Description
Hikma Pharmaceuticals PLC
ISIN : NZMEEE0005S5
Share Class Description:
DIFX:HIK: DRTotal Employee Number:
9,603Compare
Compare
Traded in other countries / regions
HIK.UKHKMPF.USAH5P.GermanyHIK.United Arab EmiratesHIKN.Mexico IPO Date
2006-04-26Description
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.15 | |||||
Equity-to-Asset | 0.46 | |||||
Debt-to-Equity | 0.62 | |||||
Debt-to-EBITDA | 1.91 | |||||
Interest Coverage | 7.18 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 2.69 | |||||
Beneish M-Score | -2.48 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 6.9 | |||||
3-Year EBITDA Growth Rate | 17 | |||||
3-Year EPS without NRI Growth Rate | 4.5 | |||||
3-Year FCF Growth Rate | -32.8 | |||||
3-Year Book Growth Rate | 3.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 5.61 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 4.12 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.82 | |||||
Quick Ratio | 1.06 | |||||
Cash Ratio | 0.17 | |||||
Days Inventory | 206.54 | |||||
Days Sales Outstanding | 109.73 | |||||
Days Payable | 88.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Dividend Growth Rate | 13.2 | |||||
Shareholder Yield % | 0.04 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 43.03 | |||||
Operating Margin % | 18.88 | |||||
Net Margin % | 11.99 | |||||
EBITDA Margin % | 25.22 | |||||
FCF Margin % | 3.55 | |||||
OCF Margin % | 13.02 | |||||
ROE % | 15.86 | |||||
ROA % | 7.21 | |||||
ROIC % | 10.4 | |||||
3-Year ROIIC % | 8.25 | |||||
ROC (Joel Greenblatt) % | 25.88 | |||||
ROCE % | 16.42 | |||||
Years of Profitability over Past 10-Year | 9 | |||||
Moat Score | 7 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 11.63 | |||||
Forward PE Ratio | 2.36 | |||||
PE Ratio without NRI | 9.31 | |||||
Shiller PE Ratio | 19.65 | |||||
Price-to-Owner-Earnings | 20.41 | |||||
PEG Ratio | 2.22 | |||||
PS Ratio | 1.4 | |||||
PB Ratio | 1.77 | |||||
Price-to-Tangible-Book | 3.23 | |||||
Price-to-Free-Cash-Flow | 39.03 | |||||
Price-to-Operating-Cash-Flow | 10.74 | |||||
EV-to-EBIT | 9.61 | |||||
EV-to-EBITDA | 6.9 | |||||
EV-to-Revenue | 1.74 | |||||
EV-to-FCF | 48.59 | |||||
Price-to-GF-Value | 0.74 | |||||
Price-to-Projected-FCF | 0.8 | |||||
Price-to-DCF (Earnings Based) | 0.17 | |||||
Price-to-DCF (FCF Based) | 0.83 | |||||
Price-to-Median-PS-Value | 0.57 | |||||
Price-to-Graham-Number | 1.16 | |||||
Earnings Yield (Greenblatt) % | 10.41 | |||||
FCF Yield % | 2.71 | |||||
Forward Rate of Return (Yacktman) % | 11.03 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Hikma Pharmaceuticals PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 3,349 | ||
| EPS (TTM) ($) | 3.62 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | -61.75 | ||
| 3-Year Sortino Ratio | -3.46 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR ($) | - | ||
| 20-Day SMA ($) | 10.23 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 10.23 - 10.23 | ||
| Shares Outstanding (Mil) | 105.18 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Hikma Pharmaceuticals PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Hikma Pharmaceuticals PLC Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2026 | 2026-08-06 | In 17 days | ||
| General meeting for 2025 | 2026-04-23 10:00 | 10.23 (+0.00%) | ||
| Guidance call for 2026 | 2026-04-23 08:30 | 10.23 (+0.00%) | ||
| Annual report for 2025 | 2026-03-18 | 10.23 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-26 09:30 | 10.23 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-26 | 10.23 (+0.00%) | ||
| Second quarter earnings conference call for 2025 | 2025-08-07 08:00 | 10.23 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-07 | 10.23 (+0.00%) | ||
| General meeting for 2024 | 2025-04-24 11:30 | 10.23 (+0.00%) | ||
| Annual report for 2024 | 2025-03-14 | 10.23 (+0.00%) |
Show
Entries
Hikma Pharmaceuticals PLC Frequently Asked Questions
What is Hikma Pharmaceuticals PLC(DIFX:HIK)'s stock price today?
The current price of DIFX:HIK is $10.23. The 52 week high of DIFX:HIK is $10.23 and 52 week low is $10.23.
When is next earnings date of Hikma Pharmaceuticals PLC(DIFX:HIK)?
The next earnings date of Hikma Pharmaceuticals PLC(DIFX:HIK) is 2026-08-06.
Does Hikma Pharmaceuticals PLC(DIFX:HIK) pay dividends? If so, how much?
Hikma Pharmaceuticals PLC(DIFX:HIK) does not pay dividend.
Press Release
Articles on Hikma Pharmaceuticals PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers